NASDAQ:FLKS - Flex Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.69
▼ -0.01 (-1.43%)
Get New Flex Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FLKS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FLKS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Flex Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.69.

This chart shows the closing price for FLKS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Flex Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2018Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
6/13/2018LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$12.00N/A
5/3/2018HC WainwrightReiterated RatingBuy$40.00High
3/27/2018Cantor FitzgeraldSet Price TargetHold$6.00High
3/7/2018Cantor FitzgeraldReiterated RatingHold$6.00Low
1/25/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$12.00High
1/17/2018Cantor FitzgeraldReiterated RatingHold$10.00High
1/3/2018Roth CapitalReiterated RatingBuy ➝ Buy$12.00Low
11/6/2017Cantor FitzgeraldReiterated RatingHold$10.00N/A
9/25/2017Cantor FitzgeraldReiterated RatingHold$10.00Medium
9/7/2017Roth CapitalInitiated CoverageBuy$14.00Low
5/4/2017Jefferies Financial GroupLower Price TargetBuy$9.00 ➝ $8.00High
3/11/2017Jefferies Financial GroupReiterated RatingBuy$11.00 ➝ $9.00N/A
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$12.00Low
1/24/2017Piper Jaffray CompaniesSet Price TargetBuy$15.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Flex Pharma logo
Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $0.69
Low: $0.67
High: $0.72

50 Day Range

MA: $6.86
Low: $0.57
High: $14.51

52 Week Range

Now: $0.69
Low: $0.26
High: $1.49

Volume

215,407 shs

Average Volume

2,030,504 shs

Market Capitalization

$12.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Flex Pharma?

The following Wall Street research analysts have issued stock ratings on Flex Pharma in the last year:
View the latest analyst ratings for FLKS.

What is the current price target for Flex Pharma?

0 Wall Street analysts have set twelve-month price targets for Flex Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Flex Pharma in the next year.
View the latest price targets for FLKS.

What is the current consensus analyst rating for Flex Pharma?

Flex Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FLKS.

How do I contact Flex Pharma's investor relations team?

Flex Pharma's physical mailing address is 31 St. James Avenue 6thFloor, Boston MA, 02116. The biotechnology company's listed phone number is 617-874-1821 and its investor relations email address is [email protected] The official website for Flex Pharma is www.flex-pharma.com.